Megalabs Irbeprex 150 mg

Megalabs Irbeprex 150 mg is a pharmaceutical product containing Irbesartan, a medication primarily prescribed to manage hypertension (high blood pressure) and protect kidney function in patients with type 2 diabetes. The brand, Irbeprex, is marketed by Megalabs, a major pharmaceutical powerhouse in the Latin American market.

The brand's story is deeply tied to the strategic evolution of its parent company. Megalabs traces its roots back to 2002, when it was formed through a merger of established regional firms. For many years, it operated under the name Mega Pharma before rebranded to Megalabs to unify its operations across more than 20 countries.

Today, Megalabs is a subsidiary of a private investment group controlled by the Strüngmann family, who are renowned German investors in the healthcare sector and former founders of generic drugmaker Hexal AG (later sold to Novartis). While headquartered in Uruguay, where its primary manufacturing and R&D hub is located, the company maintains a vast network of 18 production sites across Latin America, ensuring regional supply of its extensive pharmaceutical portfolio.